India Image-Guided Therapy Systems Market Size & Outlook, 2025-2033
India Image-Guided Therapy Systems Market Insights
- Based on Reed Intelligence findings, the India Image-Guided Therapy Systems Market reached USD 251.89 Million in 2024 and is estimated to attain USD 403.15 Million by 2033.
- From 2026 to 2033, the India market is expected to grow at a steady CAGR of 5.38%.
- Within the By Product category, Computed Tomography (CT) Scanners dominated in 2024 in terms of market size contribution.
- Over the forecast period, Positron Emission Tomography (PET) is forecasted to deliver the fastest growth, positioning it as the most lucrative By Product segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2024, India accounted for 4.94% of the global Image-Guided Therapy Systems Market size.
- By 2033, United States is expected to lead the global Image-Guided Therapy Systems Market in terms of market size.
- Within Asia Pacific, China is projected to dominate the regional Image-Guided Therapy Systems Market size by 2033.
- India is identified as the fastest-growing market in Asia Pacific, anticipated to reach USD 403.69 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 251.89 Million |
| Market Size In 2033 | USD 403.15 Million |
| Largest segment | Computed Tomography (CT) Scanners |
| Units | Revenue in USD Million |
| CAGR | 5.38% (2025-2033) |
| Segmnetation Covered | |
| By Product |
|
| By Application |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
India Image-Guided Therapy Systems Market By Product 2025-2033 (USD Million)
| By Product | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Computed Tomography (CT) Scanners | XX.x | XX.x | XX.x | 86.8 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ultrasound Systems | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Magnetic Resonance Imaging (MRI) | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Endoscope | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| X-ray Fluoroscopy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Positron Emission Tomography (PET) | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Single Photon Emission Computed Tomography (SPECT) | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
India Image-Guided Therapy Systems Market By Application 2025-2033 (USD Million)
| By Application | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiac Surgery | XX.x | XX.x | XX.x | 76.4 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Neurosurgery | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Orthopedic Surgery | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Urology | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Gastroenterology | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Oncology Surgery | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
